GE Healthcare Partners With Tesla Engineering to Produce Ultra High-Field 7T MRI Systems

May 20, 2014 — GE Healthcare and Tesla Engineering Ltd. are collaborating to produce 7T human whole-body magnetic resonance imaging (MRI) scanners. The companies made the announcement at the joint meeting of the International Society for Magnetic Resonance in Medicine (ISMRM) and the European Society for Magnetic Resonance in Medicine and Biology (ESMRMB) in Milan.

Ultra high-field MRI systems are used for scientific and medical research, primarily for morphological and functional imaging of the brain while steadily expanding to all anatomies. Researchers using ultra high-field scanners hope their work will contribute to earlier disease detection, more accurate diagnosis and increased effectiveness of investigational therapies for disorders and diseases such as cancer, stroke, epilepsy, drug abuse, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, attention deficit disorder, multiple sclerosis, head injury, visual disorders and schizophrenia.

Tesla Engineering Ltd. is currently building a new factory in Storrington, U.K., to manufacture the 7 Tesla magnets. They have recruited several key engineering and management staff with extensive experience in the design and manufacturing of ultra high-field magnets. The first unit from the new production line is committed to GE and scheduled to ship in late 2015.

“This agreement will enable GE to deepen and broaden our collaborations with leading MRI academics and visionaries, sharing our collective expertise and missions in technology, science and medicine,” said Richard Hausmann, president and CEO of GE Healthcare, MR. “The GE 7T community in the U.S., Europe and Asia has already demonstrated breakthrough observations and understanding of Alzheimer’s disease, traumatic brain injury and cognitive physiology. Together, we will continue to push the frontiers of MRI for neuroscience and other applications.”

“Tesla is very pleased to collaborate with GE and to take a leadership position in the continuing evolution of MR magnet technology,” said Mike Begg, group managing director, Tesla Engineering Ltd. “This is a solid business opportunity for us that complements and builds upon our existing strengths in superconducting magnet technology, as well as our strong core technology positions in cryogenics.”

For more information: www.gehealthcare.com, www.tesla.co.uk


Related Content

News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
News | Radiology Imaging

Jan. 15, 2025 — University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE ...

Time January 27, 2025
arrow
News | Contrast Media

Jan. 10, 2025 – Bayer has announced positive topline results of the Phase III QUANTI studies evaluating the efficacy and ...

Time January 14, 2025
arrow
News | Women's Health

Aug. 19, 2024 — GE HealthCare recently announced a collaboration with the University of California San Diego School of ...

Time August 29, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 23, 2024 — Researchers at the National Institutes of Health (NIH) found that an artificial intelligence (AI) model ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 17, 2024 — Hyperfine, a groundbreaking medical device company that has redefined brain imaging with the world’s ...

Time July 17, 2024
arrow
News | Prostate Cancer

July 11, 2024 — GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence ...

Time July 11, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
Subscribe Now